hydroxychloroquine has been researched along with Cystic Fibrosis in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Morlacchi, LC | 1 |
Rossetti, V | 1 |
Gigli, L | 1 |
Amati, F | 1 |
Rosso, L | 1 |
Aliberti, S | 1 |
Nosotti, M | 1 |
Blasi, F | 1 |
Giglia, M | 1 |
Beci, G | 1 |
Rosselli Del Turco, E | 1 |
Guardigni, V | 1 |
Amedeo, A | 1 |
Cucchetto, G | 1 |
Verucchi, G | 1 |
Cipolli, M | 1 |
Calza, L | 1 |
Viale, P | 1 |
Rayess, N | 1 |
Patel, VR | 1 |
Sagransky, DM | 1 |
Greenwald, RA | 1 |
Gorvoy, JD | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients[NCT05116748] | 200 participants (Anticipated) | Observational | 2021-10-01 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
4 other studies available for hydroxychloroquine and Cystic Fibrosis
Article | Year |
---|---|
COVID-19 in lung transplant recipients: A case series from Milan, Italy.
Topics: Aged; Anti-Bacterial Agents; Anticoagulants; Blood Gas Analysis; COVID-19; COVID-19 Drug Treatment; | 2020 |
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cysti | 2020 |
Bilateral Severe Decreased Vision With Normal Examination Findings.
Topics: Adult; Antibiotics, Antineoplastic; Antirheumatic Agents; Autoimmune Diseases; Cataract; Cystic Fibr | 2018 |
Seropositive rheumatoid arthritis in a patient with cystic fibrosis.
Topics: Adolescent; Arthritis, Juvenile; Cystic Fibrosis; Female; Gold Sodium Thiomalate; Humans; Hydroxychl | 1980 |